ValuEngine lowered shares of Athersys, Inc. (NASDAQ:ATHX) from a hold rating to a sell rating in a research note published on Monday.

Several other equities research analysts have also recently weighed in on ATHX. Maxim Group set a $12.00 target price on shares of Athersys and gave the company a buy rating in a research note on Monday, August 7th. Zacks Investment Research upgraded shares of Athersys from a hold rating to a buy rating and set a $1.75 target price for the company in a research note on Monday, August 14th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The stock has an average rating of Buy and an average target price of $7.17.

Shares of Athersys (NASDAQ ATHX) opened at 2.14 on Monday. The firm’s 50-day moving average price is $2.01 and its 200 day moving average price is $1.63. Athersys has a 52 week low of $1.02 and a 52 week high of $2.63. The firm’s market cap is $243.77 million.

Athersys (NASDAQ:ATHX) last released its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.06). Athersys had a negative net margin of 729.07% and a negative return on equity of 121.47%. The business had revenue of $0.67 million during the quarter, compared to analysts’ expectations of $0.96 million. During the same quarter last year, the company earned ($0.08) earnings per share. The firm’s revenue was up 12.4% on a year-over-year basis. Equities analysts anticipate that Athersys will post ($0.24) EPS for the current year.

COPYRIGHT VIOLATION WARNING: “ValuEngine Lowers Athersys, Inc. (ATHX) to Sell” was reported by Watch List News and is the property of of Watch List News. If you are reading this news story on another domain, it was illegally copied and republished in violation of United States and international trademark & copyright law. The correct version of this news story can be read at

In other Athersys news, EVP John J. Harrington sold 15,000 shares of the firm’s stock in a transaction dated Monday, September 18th. The shares were sold at an average price of $2.17, for a total transaction of $32,550.00. Following the completion of the transaction, the executive vice president now owns 679,416 shares in the company, valued at $1,474,332.72. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 9.40% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently made changes to their positions in the business. Wells Fargo & Company MN lifted its stake in Athersys by 4.8% during the first quarter. Wells Fargo & Company MN now owns 61,176 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 2,800 shares during the period. Bank of America Corp DE lifted its stake in Athersys by 17.2% during the first quarter. Bank of America Corp DE now owns 61,580 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 9,019 shares during the period. SG Americas Securities LLC lifted its stake in Athersys by 329.7% during the second quarter. SG Americas Securities LLC now owns 73,434 shares of the biopharmaceutical company’s stock worth $111,000 after purchasing an additional 56,345 shares during the period. State of Wisconsin Investment Board bought a new position in Athersys during the second quarter worth about $113,000. Finally, Blair William & Co. IL lifted its stake in Athersys by 708.0% during the second quarter. Blair William & Co. IL now owns 80,804 shares of the biopharmaceutical company’s stock worth $122,000 after purchasing an additional 70,804 shares during the period. Hedge funds and other institutional investors own 19.08% of the company’s stock.

About Athersys

Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Athersys Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.